Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 370

1.

Distinguishing lupus anticoagulants from factor VIII inhibitors in haemophilic and non-haemophilic patients.

Rampersad AG, Boylan B, Miller CH, Shapiro A.

Haemophilia. 2018 Jul 13. doi: 10.1111/hae.13565. [Epub ahead of print]

PMID:
30004159
2.

Breaking with tradition: A scoping meta-analysis analyzing the effects of student-centered learning and computer-aided instruction on student performance in anatomy.

Wilson AB, Brown KM, Misch J, Miller CH, Klein BA, Taylor MA, Goodwin M, Boyle EK, Hoppe C, Lazarus MD.

Anat Sci Educ. 2018 Apr 16. doi: 10.1002/ase.1789. [Epub ahead of print]

PMID:
29659155
3.

Reagent substitutions in the Centers for Disease Control and Prevention Nijmegen-Bethesda assay for factor VIII inhibitors.

Miller CH, Payne AB, Driggers J, Ellingsen D, Boylan B, Bean CJ.

Haemophilia. 2018 Mar 24. doi: 10.1111/hae.13434. [Epub ahead of print] No abstract available.

PMID:
29573516
4.

Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels.

Boylan B, Miller CH.

Haemophilia. 2018 Feb 20. doi: 10.1111/hae.13435. [Epub ahead of print]

PMID:
29461004
5.

Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.

Miller CH.

Haemophilia. 2018 Mar;24(2):186-197. doi: 10.1111/hae.13424. Epub 2018 Feb 15. Review.

6.

Behavioral Evolution: Can You Dig It?

Sheehan MJ, Miller CH, Vogt CC, Ligon RA.

Curr Biol. 2018 Jan 8;28(1):R19-R21. doi: 10.1016/j.cub.2017.11.016.

PMID:
29316414
7.

Empirical evidence of fixed and homeostatic patterns of polyploid advantage in a keystone grass exposed to drought and heat stress.

Godfree RC, Marshall DJ, Young AG, Miller CH, Mathews S.

R Soc Open Sci. 2017 Nov 22;4(11):170934. doi: 10.1098/rsos.170934. eCollection 2017 Nov.

8.

Utilizing Respiratory Therapists to Reduce Costs of Care.

Becker EA, Hoerr CA, Wiles KS, Skees DL, Miller CH, Laher DS.

Respir Care. 2018 Jan;63(1):102-117. doi: 10.4187/respcare.05808. Epub 2017 Nov 28.

PMID:
29184048
9.

Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors.

Miller CH, Boylan B, Shapiro AD, Lentz SR, Wicklund BM; Hemophilia Inhibitor Research Study Investigators.

J Thromb Haemost. 2017 Oct;15(10):1971-1976. doi: 10.1111/jth.13795. Epub 2017 Sep 14.

10.

A meta-analysis of anatomy laboratory pedagogies.

Wilson AB, Miller CH, Klein BA, Taylor MA, Goodwin M, Boyle EK, Brown K, Hoppe C, Lazarus M.

Clin Anat. 2018 Jan;31(1):122-133. doi: 10.1002/ca.22934. Epub 2017 Jul 6.

PMID:
28612403
11.

Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay.

Boylan B, Rice AS, Neff AT, Manco-Johnson MJ, Kempton CL, Miller CH; Hemophilia Inhibitor Research Study Investigators.

J Thromb Haemost. 2016 Oct;14(10):1931-1940. doi: 10.1111/jth.13438. Epub 2016 Sep 17.

12.

RBP-J-Regulated miR-182 Promotes TNF-α-Induced Osteoclastogenesis.

Miller CH, Smith SM, Elguindy M, Zhang T, Xiang JZ, Hu X, Ivashkiv LB, Zhao B.

J Immunol. 2016 Jun 15;196(12):4977-86. doi: 10.4049/jimmunol.1502044. Epub 2016 May 9.

13.

Improving the performance of factor VIII inhibitor tests in hemophilia A.

Miller CH.

Thromb Res. 2015 Dec;136(6):1047-8. doi: 10.1016/j.thromres.2015.09.019. Epub 2015 Sep 28. No abstract available.

14.

Meta-analysis of Functional Neuroimaging of Major Depressive Disorder in Youth.

Miller CH, Hamilton JP, Sacchet MD, Gotlib IH.

JAMA Psychiatry. 2015 Oct;72(10):1045-53. doi: 10.1001/jamapsychiatry.2015.1376.

PMID:
26332700
15.

Game, set, match for factor VIII mismatch?

Miller CH.

Blood. 2015 Aug 13;126(7):829-30. doi: 10.1182/blood-2015-02-625574.

16.

Characteristics of hemophilia patients with factor VIII inhibitors detected by prospective screening.

Miller CH, Rice AS, Boylan B, Payne AB, Kelly FM, Escobar MA, Gill J, Leissinger C, Soucie JM; Hemophilia Inhibitor Research Study Investigators.

Am J Hematol. 2015 Oct;90(10):871-6. doi: 10.1002/ajh.24104. Epub 2015 Sep 10.

17.

Cluster of inhibitors among adult inpatients with haemophilia in a single institution.

Ishaku NG, Key NS, Miller CH, Nielsen B, Buckner T, Chen SL, Hooper WC, Soucie JM.

Haemophilia. 2015 Jul;21(4):e325-8. doi: 10.1111/hae.12697. Epub 2015 May 4. No abstract available.

PMID:
25939561
18.

Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations.

Boylan B, Rice AS, De Staercke C, Eyster ME, Yaish HM, Knoll CM, Bean CJ, Miller CH; Hemophilia Inhibitor Research Study Investigators.

J Thromb Haemost. 2015 Jun;13(6):1036-42. doi: 10.1111/jth.12902. Epub 2015 May 9.

19.

Intraosseous infusion rates under high pressure: a cadaveric comparison of anatomic sites.

Pasley J, Miller CH, DuBose JJ, Shackelford SA, Fang R, Boswell K, Halcome C, Casey J, Cotter M, Matsuura M, Relph N, Tarmey NT, Stein DM.

J Trauma Acute Care Surg. 2015 Feb;78(2):295-9. doi: 10.1097/TA.0000000000000516.

PMID:
25757113
20.

Impact of inhibitors on hemophilia A mortality in the United States.

Walsh CE, Soucie JM, Miller CH; United States Hemophilia Treatment Center Network.

Am J Hematol. 2015 May;90(5):400-5. doi: 10.1002/ajh.23957. Epub 2015 Feb 5.

21.

Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.

Boylan B, Rice AS, Dunn AL, Tarantino MD, Brettler DB, Barrett JC, Miller CH; Hemophilia Inhibitor Research Study Investigators; Hemophilia Inhibitor Research Study Investigators.

J Thromb Haemost. 2015 Jan;13(1):47-53. doi: 10.1111/jth.12768. Epub 2014 Dec 11.

22.

RBP-J imposes a requirement for ITAM-mediated costimulation of osteoclastogenesis.

Li S, Miller CH, Giannopoulou E, Hu X, Ivashkiv LB, Zhao B.

J Clin Invest. 2014 Nov;124(11):5057-73. doi: 10.1172/JCI71882. Epub 2014 Oct 20.

23.

A public health approach to the prevention of inhibitors in hemophilia.

Soucie JM, Miller CH, Kelly FM, Oakley M, Brown DL, Kucab P.

Am J Prev Med. 2014 Nov;47(5):669-73. doi: 10.1016/j.amepre.2014.07.007. Epub 2014 Sep 19.

24.

Analysis of mouse model pathology: a primer for studying the anatomic pathology of genetically engineered mice.

Cardiff RD, Miller CH, Munn RJ.

Cold Spring Harb Protoc. 2014 Jun 2;2014(6):561-80. doi: 10.1101/pdb.top069922.

PMID:
24890215
25.

Manual immunohistochemistry staining of mouse tissues using the avidin-biotin complex (ABC) technique.

Cardiff RD, Miller CH, Munn RJ.

Cold Spring Harb Protoc. 2014 Jun 2;2014(6):659-62. doi: 10.1101/pdb.prot073429.

PMID:
24890206
26.

Manual hematoxylin and eosin staining of mouse tissue sections.

Cardiff RD, Miller CH, Munn RJ.

Cold Spring Harb Protoc. 2014 Jun 2;2014(6):655-8. doi: 10.1101/pdb.prot073411.

PMID:
24890205
27.

Females with FVIII and FIX deficiency have reduced joint range of motion.

Sidonio RF, Mili FD, Li T, Miller CH, Hooper WC, DeBaun MR, Soucie M; Hemophilia Treatment Centers Network.

Am J Hematol. 2014 Aug;89(8):831-6. doi: 10.1002/ajh.23754. Epub 2014 May 21.

28.

Vested interest, disaster preparedness, and strategic campaign message design.

Adame BJ, Miller CH.

Health Commun. 2015;30(3):271-81. doi: 10.1080/10410236.2013.842527. Epub 2014 May 16.

PMID:
24837442
29.

High factor VIII, von Willebrand factor, and fibrinogen levels and risk of venous thromboembolism in blacks and whites.

Payne AB, Miller CH, Hooper WC, Lally C, Austin HD.

Ethn Dis. 2014 Spring;24(2):169-74.

30.

Mouse tissue fixation.

Cardiff RD, Miller CH, Munn RJ.

Cold Spring Harb Protoc. 2014 May 1;2014(5). pii: pdb.prot073403. doi: 10.1101/pdb.prot073403.

PMID:
24786501
31.

Limited mouse necropsy.

Cardiff RD, Miller CH, Munn RJ.

Cold Spring Harb Protoc. 2014 May 1;2014(5). pii: pdb.prot073395. doi: 10.1101/pdb.prot073395.

PMID:
24786500
32.

Laboratory testing for factor inhibitors.

Favaloro EJ, Verbruggen B, Miller CH.

Haemophilia. 2014 May;20 Suppl 4:94-8. doi: 10.1111/hae.12408. Review.

PMID:
24762283
33.

Gender, race and diet affect platelet function tests in normal subjects, contributing to a high rate of abnormal results.

Miller CH, Rice AS, Garrett K, Stein SF.

Br J Haematol. 2014 Jun;165(6):842-53. doi: 10.1111/bjh.12827. Epub 2014 Mar 12.

34.

National surveillance for hemophilia inhibitors in the United States: Summary report of an expert meeting.

Soucie JM, Miller CH, Kelly FM, Aschman D, DiMichele D, Konkle BA, Kulkarni R, Monahan PE; CDC Inhibitor Surveillance Working Group.

Am J Hematol. 2014 Jun;89(6):621-5. doi: 10.1002/ajh.23704. Epub 2014 Apr 10.

35.

The CDC Hemophilia B mutation project mutation list: a new online resource.

Li T, Miller CH, Payne AB, Craig Hooper W.

Mol Genet Genomic Med. 2013 Nov;1(4):238-45. doi: 10.1002/mgg3.30. Epub 2013 Aug 19.

36.

Mutation analysis of a cohort of US patients with hemophilia B.

Li T, Miller CH, Driggers J, Payne AB, Ellingsen D, Hooper WC.

Am J Hematol. 2014 Apr;89(4):375-9. doi: 10.1002/ajh.23645. Epub 2014 Mar 3.

37.

An advisory program for first- and second-year medical students: the Weill Cornell experience.

Drusin LM, Gerber LM, Miller CH, Storey-Johnson CL, Ballard BL.

Med Educ Online. 2013 Nov 29;18:22684. doi: 10.3402/meo.v18i0.22684.

38.

A study of prospective surveillance for inhibitors among persons with haemophilia in the United States.

Soucie JM, Miller CH, Kelly FM, Payne AB, Creary M, Bockenstedt PL, Kempton CL, Manco-Johnson MJ, Neff AT; Haemophilia Inhibitor Research Study Investigators.

Haemophilia. 2014 Mar;20(2):230-7. doi: 10.1111/hae.12302. Epub 2013 Nov 22.

39.

Structured reporting in anatomic pathology for coclinical trials: the caELMIR model.

Cardiff RD, Miller CH, Munn RJ, Galvez JJ.

Cold Spring Harb Protoc. 2014 Jan 1;2014(1):32-43. doi: 10.1101/pdb.top078790.

PMID:
24173313
40.

Morphological differences of primary cilia between human induced pluripotent stem cells and their parental somatic cells.

Nathwani BB, Miller CH, Yang TL, Solimano JL, Liao JC.

Stem Cells Dev. 2014 Jan 15;23(2):115-23. doi: 10.1089/scd.2013.0162. Epub 2013 Oct 8.

PMID:
24007236
41.

Inoculation message treatments for curbing noncommunicable disease development.

Mason AM, Miller CH.

Rev Panam Salud Publica. 2013 Jul;34(1):29-35.

42.

Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study.

Miller CH, Rice AS, Boylan B, Shapiro AD, Lentz SR, Wicklund BM, Kelly FM, Soucie JM; Hemophilia Inhibitor Research Study Investigators.

J Thromb Haemost. 2013 Jul;11(7):1300-9. doi: 10.1111/jth.12259.

43.

Quantitation of fixative-induced morphologic and antigenic variation in mouse and human breast cancers.

Cardiff RD, Hubbard NE, Engelberg JA, Munn RJ, Miller CH, Walls JE, Chen JQ, Velásquez-García HA, Galvez JJ, Bell KJ, Beckett LA, Li YJ, Borowsky AD.

Lab Invest. 2013 Apr;93(4):480-97. doi: 10.1038/labinvest.2013.10. Epub 2013 Feb 11.

44.

Pharmacological properties and predicted binding mode of arylmethylene quinuclidine-like derivatives at the α3β4 nicotinic acetylcholine receptor (nAChR).

Kombo DC, Hauser TA, Grinevich VP, Melvin MS, Strachan JP, Sidach SS, Chewning J, Fedorov N, Tallapragada K, Breining SR, Miller CH.

Bioorg Med Chem Lett. 2013 Mar 1;23(5):1450-5. doi: 10.1016/j.bmcl.2012.12.054. Epub 2012 Dec 28.

PMID:
23352509
45.

The CDC Hemophilia A Mutation Project (CHAMP) mutation list: a new online resource.

Payne AB, Miller CH, Kelly FM, Michael Soucie J, Craig Hooper W.

Hum Mutat. 2013 Feb;34(2):E2382-91. doi: 10.1002/humu.22247. Epub 2012 Dec 26.

46.

Discovery of (2S,3R)-N-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]benzo[b]furan-2-carboxamide (TC-5619), a selective α7 nicotinic acetylcholine receptor agonist, for the treatment of cognitive disorders.

Mazurov AA, Kombo DC, Hauser TA, Miao L, Dull G, Genus JF, Fedorov NB, Benson L, Sidach S, Xiao Y, Hammond PS, James JW, Miller CH, Yohannes D.

J Med Chem. 2012 Nov 26;55(22):9793-809. doi: 10.1021/jm301048a. Epub 2012 Nov 13.

PMID:
23126648
47.

Superresolution STED microscopy reveals differential localization in primary cilia.

Yang TT, Hampilos PJ, Nathwani B, Miller CH, Sutaria ND, Liao JC.

Cytoskeleton (Hoboken). 2013 Jan;70(1):54-65. doi: 10.1002/cm.21090. Epub 2012 Nov 16.

PMID:
23125024
48.

Vested Interest theory and disaster preparedness.

Miller CH, Adame BJ, Moore SD.

Disasters. 2013 Jan;37(1):1-27. doi: 10.1111/j.1467-7717.2012.01290.x. Epub 2012 Oct 10.

PMID:
23050780
49.

Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a novel highly selective α4β2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders.

Mazurov AA, Miao L, Bhatti BS, Strachan JP, Akireddy S, Murthy S, Kombo D, Xiao YD, Hammond P, Zhang J, Hauser TA, Jordan KG, Miller CH, Speake JD, Gatto GJ, Yohannes D.

J Med Chem. 2012 Nov 8;55(21):9181-94. doi: 10.1021/jm3006542. Epub 2012 Jul 27.

PMID:
22793665
50.

Utility of multiplex ligation-dependent probe amplification (MLPA) for hemophilia mutation screening.

Payne AB, Bean CJ, Hooper WC, Miller CH.

J Thromb Haemost. 2012 Sep;10(9):1951-4. doi: 10.1111/j.1538-7836.2012.04843.x. No abstract available.

Supplemental Content

Loading ...
Support Center